UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

DEX-0315

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an

revention entitled: COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIF.	IC GENES AND PROTEINS
COMI OSITIONS AND METHODS RELATING TO OVARDAN SI ECH.	\$ # # # # # # # # # # # # # # # # # # #
	mis E
ind invented by: Susana Salceda; Roberto Macina; Ping Hu; Herve Recipon; Kalpana Karr	a; Robert Cafferkey;
Yongming Sun; and Chenghua Liu;	
CONTINUATION APPLICATION, check appropriate box and supply th	ne requisite information:
발 ⑤ Continuation Divisional Continuation-in-part (CIP)	
hich is a:	
Continuation 🔲 Divisional 🔲 Continuation-in-part (CIP)	of prior application No.:
Which is a:	
Continuation Divisional Continuation-in-part (CIP)	of prior application No.:
Enclosed are:	
Application Elements	
1. Filing fee as calculated and transmitted as described below	
Filing fee as calculated and transmitted as described below	
2. Specification having pages and inc	cluding the following:
a. 🗵 Descriptive Title of the Invention	
b. 🗵 Cross References to Related Applications (if applicable)	
c. Statement Regarding Federally-sponsored Research/Dev	velopment (if applicable)
d. Reference to Sequence Listing, a Table, or a Computer P	
e. 🗵 Background of the Invention	3 11
•	
f. Brief Summary of the Invention Fig. 2. St. (1.5) Support to the Province (1.5) (1.5) (1.5)	
g. Brief Description of the Drawings (if filed)	
h. 🗵 Detailed Description	
i. ⊠ Claim(s) as Classified Below	
j. 🛛 Abstract of the Disclosure	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0315

Total Pages in this Submission

	Application Elements (Continued)									
3.		Drawing(s) (when necessary as prescribed by 35 USC 113)								
	a.	☐ Formal Number of Sheets								
	b.	☐ Informal Number of Sheets								
4.	X									
	a.	☐ Newly executed (original or copy) ☑ Unexecuted								
٠.	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)								
	c.	☑ With Power of Attorney ☐ Without Power of Attorney								
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.								
6 .		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)								
7.		Application Data Sheet (See 37 CFR 1.76)								
7. 138. 138.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)								
i i	a.	☑ Computer Readable Form (CRF)								
	b.	Specification Sequence Listing on:								
ij		i. CD-ROM or CD-R (2 copies); or								
		ii. 🗵 Paper								
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy								
		Accompanying Application Parts								
9.		Assignment Papers (cover sheet & document(s))								
10.		37 CFR 3.73(B) Statement (when there is an assignee)								
11.		English Translation Document (if applicable)								
12.		Information Disclosure Statement/PTO-1449 Copies of IDS Citations								
13.		Preliminary Amendment								
14.		Return Receipt Postcard (MPEP 503) (Should be specifically itemized)								
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)								
16.	\boxtimes	Certificate of Mailing								
		☐ First Class ☒ Express Mail (Specify Label No.): EV 017478642 US								

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

was unintentional.

Total Pages in this Submission

Docket No.

DEX-0315

7.	M	Additional Enclosures (please identify below): Acknowledgment Postcard.
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
3.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing
		of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of

country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice

Accompanying Application Parts (Continued)

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0315

Total Pages in this Submission

Foo	Calcu	ılation	and	Tranc	mittal

		CLAIMS	AS FILED			
For	#Filed	#Allowed	#Extra		Rate	Fee
otal Claims	19	- 20 =	0	х	\$18.00	\$0.00
ndep. Claims	2	- 3 =	0	х	\$84.00	\$0.00
i Aultiple Dependent Cl	aims (check if	applicable)	×			\$280.00
Harry					BASIC FEE	\$740.00
OTHER FEE (specify	purpose)					\$0.00
					TOTAL FILING FEE	\$1,020.00
Credit any	e amount of overpayment. Iy additional filir	ng fees required	as filing fee. under 37 C.l	F.R. 1.16	and 1.17.	
☑ Charge the						
pursuant to pursua	o 37 C.F.R. 1.3	11(b).	(-/- •	/	Signature A. Tyrrell, Reg. No. 38,350	
;			6	6 East M	Tyrrell P.C. ain Street N.J. 08053	

Tel: 856-810-1515 Fax: 856-810-1454

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV 017478642 US Date of Deposit: February 13, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.A. 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

- Patent Application Transmittal Letter (in duplicate);
- 2) Application consisting of 144 pages of Specification, including 3 pages of Claims and 1 page of Abstract;
- 3) Trust Check in the amount of \$1,020.00;
- 4) Return Postcard;
- 5) Unexecuted Declaration and Power of Attorney;
- 6) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 7) Paper copy of Sequence listing; and
- 8) Diskette containing computer readable copy of Sequence Listing.

Mathles A. Tym Kathleen A. Tymrell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

3 3 . .

Attorney Docket No.:

DEX-0315

Inventors:

Salceda et al.

Serial No.:

Not yet assigned

Filing Date:

Herewith

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Compositions and Methods Relating to Ovarian Specific Genes and Proteins

"Express Mail" Label No. EV 017478642 US Date of Deposit - February 13, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202.

U.S. Patent and Trademark Office

BOX SEQUENCE, PO Box 2327

Arlington, VA 22202

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Kathleen A. Tyrrell Registration No. 38 \$8,350

Date: February 13, 2002

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515